Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster market share

Tracy Staton

 finally launched its next-gen diabetes treatment in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes for sales, but the long-acting insulin faces new competitors that could get in the way of those ambitions.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS